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 Introduction 
 Necrobiosis lipoidica (NL) is a rare granulomatous 
skin disease of unknown origin, first described by Op-
penheimer in 1929 in association with diabetes mellitus. 
In 1935, Goldsmith reported the first case in a nondia-
betic patient  [1] . Clinically, NL appears as irregular or 
circular lesions ranging in color from red brown, dark 
purple to yellow. Ulcerations and telangiectasia may oc-
cur  [2] . Most commonly the anterior portions of the low-
er legs are involved, but other localizations have been de-
scribed  [3] . 
 Since the lesions of NL are not only aesthetically trou-
blesome, but may also be accompanied by pain or second-
arily infected ulcerations, treatment of this disease is nec-
essary. Several therapeutic approaches have been de-
scribed for NL, including topical, intralesional and 
systemic application of corticosteroids, topical retinoids, 
PUVA, cyclosporine and chloroquine  [4–9] . However, 
these treatment modalities are of limited success, and 
new approaches are wanted to handle this often frustrat-
ing and cosmetically disturbing disease.
 In 2006, Heidenheim and Jemec  [10] successfully 
treated a diabetic patient with a 10-year history of NL by 
topical photodynamic therapy (PDT). They observed a 
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 Abstract 
 Background: Necrobiosis lipoidica (NL) is a granulomatous 
skin disease of unknown origin, and no reliably effective 
treatment option exists to handle this often disfiguring dis-
ease. Recently, a patient with long-lasting NL was reported 
to be cured by topical photodynamic therapy (PDT).  Objec-
tive: To evaluate the overall potential of PDT in the treatment 
of NL on the lower legs.  Methods: Retrospective study of 18 
patients (aged 16–62 years) from 3 European university de-
partments of dermatology treated with PDT for NL. Methyl 
aminolevulinate or 5-aminolevulinic acid were used as topi-
cally applied photosensitizers. Illumination followed with 
red light-emitting diode light.  Results:  Complete response 
was seen in 1/18 patients after 9 PDT cycles, and partial re-
sponse in 6/18 patients (2–14 PDT cycles) giving an overall 
response rate of 39% (7/18).  Conclusion: Although almost 
40% of the cases showed some degree of response, PDT can-
not currently be recommended as first-line therapy of NL. 
Subpopulations of therapy-resistant NL patients may, how-
ever, benefit from PDT.  Copyright © 2008 S. Karger AG, Basel 
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complete remission of the NL lesion after 6 cycles of PDT 
using methyl aminolevulinate (MAL, 160 mg/g) and red 
light. This single case report published so far motivated 
us to perform a study in a series of patients in order to 
evaluate the overall efficacy of this therapeutic modality 
to control this often therapy-resistant and uncontrolled 
disease. 
 Patients and Methods 
This study was conducted in 3 European university depart-
ments of dermatology: Roskilde Hospital (Roskilde, Denmark), 
Ludwig Maximilian University (Munich, Germany) and the 
Faculty Hospital Královské Vinohrady (Prague, Czech Repub-
lic). Eighteen patients (14 female, 4 male) with NL of the lower 
legs and resistant to conventional therapies were included ( ta-
ble 1 ). The average age of the patients was 38 years with a range 
of 16–62 years. Comorbidity of diabetes mellitus was present in 
28% of the patients (5/18). The duration of NL was 1–8 years in 
16 patients and 19 and 26 years in 2, respectively. In 4 patients, 
lesions were partially ulcerated. A diagnostic biopsy was per-
formed in 12 patients, while in 6 there was no histological con-
firmation of the disease, but the clinical appearance was clearly 
NL. Each patient gave informed consent for the planned proce-
dure.
PDT was initiated by the topical application of a photosensi-
tizer onto the lesions. We used MAL (160 mg/g) in 15 patients and 
5-aminolevulinic acid (200 mg/g) in 3. The lesions were then cov-
ered with occlusive and light-protective dressing for 3 h. After 
removal of the dressing the MAL-treated areas (n = 15) were il-
luminated with red light at a dose of 37 J/cm 2 (Aktilite lamp, Pho-
tocure ASA, Norway) and the 5-aminolevulinic-acid-treated ar-
eas (n = 2) at a dose of 75 J/cm 2 . The third 5-aminolevulinic-acid-
treated patient received 75 J/cm 2  for the first 2 cycles and 40 J/cm 2 
 further on. During illumination, the respective areas were cooled 
in 11 patients to relieve burning sensations. Three patients re-
ceived analgesics (NSAIDs), 1 patient received local anesthesia 
with bupivacaine and 1 with mepivacaine. With respect to pain 
during illumination, patients tended to react differently during 
each session. On a 10-cm visual analog scale from 0 (no pain) to 
10 (unbearable pain), the level ranged from 2 to 10 with a median 
of 5.
 Table 1. Overview of 18 patients with NL treated with PDT 
Pa-
tient
Sex Age
years
Insti-
tution
Duration
of disease
years
Diabetes
comor-
bidity
Biopsy Treatment modalities 
prior to PDT
PDT 
cycles
Type of PDT/
energy
J/cm2
Pain
score
Cooling Interval be-
tween treat-
ment and
evaluation
Out-
come of
therapy
1 F 46 DK 6 no yes allopurinol 9 MAL/37 4 yes 3 months CR
2 F 17 CZ 2 no n.a. TS, OTS, ILS 3 MAL/37 7 yes 4 weeks PR
3 M 32 D 8 no yes TS 6 MAL/37 6 yes 6 weeks PR
4 F 62 D 26 no yes TS, cryo. 6 MAL/37 5 yes 6 weeks PR
5 M 31 DK 1 no no TS 5 MAL/37 4 no 8 weeks PR
6 F 25 DK 2 yes no OTS 14 MAL/37 5 no 4 months PR
7 M 57 DK n.a. DM2 n.a. TS, tacrolimus 2 MAL/37 n.a. no 1 year PR
8 F 57 D 4 no yes TS 8 MAL/37 2 yes 1 week NR
9 F 60 D 19 no yes TS, PUVA 6 MAL/37 7 yes 3 weeks NR
10 F 35 D 4–5 no yes TS, SS 6 MAL/37 2 yes 4 weeks NR
11 F 38 CZ 4 no yes TS, OTS, ILS 3 ALA/75 4 no 4 weeks NR
12 F 27 CZ 5 DM1 yes TS, OTS, ILS,
PUVA, imiquimod
5 ALA/40–75 4 no 6 weeks NR
13 F 19 D 3 DM2 yes PUVA (28!), 
tacrolimus
6 MAL/37 4 yes 8 weeks NR
14 F 43 D 4 no yes TS 8 MAL/37 3 yes 8 weeks NR
15 F 52 CZ 2–3 no no TS, OTS, ILS 4 ALA/75 5 no 8 weeks NR
16 M 16 DK 8 DM1 no pentoxifylline 2 MAL/37 10 yes 8 weeks NRa
17 F 17 DK 3 no yes TS 6 MAL/37 4 no 8 weeks NR
18 F 42 DK 2 no yes none 6 MAL/37 n.a. yes 1 year NR
D = Germany; DK = Denmark; CZ = Czech Republic; DM1/DM2 = diabetes mellitus type 1/2; n.a. = not assessed; TS = topical 
corticosteroids; OTS = occlusive topical corticosteroids; ILS = intralesional corticosteroids; cryo. = cryotherapy; PUVA = psoralen and 
ultraviolet A; SS = systemic corticosteroids; ALA = 5-aminolevulinic acid; CR = complete response; PR = partial response; NR = no 
response.
a Stopped due to pain.
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 Intervals between separate PDT cycles ranged from 1 to 3 
weeks. In 4 patients the intervals exceeded 1 month. The number 
of PDT cycles performed ranged from 2 to 14 per patient with an 
average of 6. These variations in the treatment protocol were ei-
ther due to a complete lack of effect, unacceptable side effects or 
the refusal of the patient to continue the treatment. 
 Results 
 The interval between PDT and evaluation of therapy 
outcome was 1 week  to 4 months in 16 patients and 1 year 
in 2. One patient showed complete response after 9 cycles, 
6 patients showed partial response after 2–14 cycles and 
11 patients showed no response ( table 1 ,  fig. 1 ). Adverse 
events included erythema of the treated areas in 9 pa-
tients, crusting in 6 patients, pustules, exudation and 
blistering, respectively, in 1 patient. The only patient with 
complete response to therapy was a 46-year-old female 
without diabetes comorbidity and with a 6-year history 
of NL located on the shins of both legs. Allopurinol (200 
mg daily for 3 months) had been given prior to MAL-PDT 
without effect. This patient’s lesions had shown ulcer-
ations and a slight hyperpigmentation at the edges. Com-
plete response was observed after 9 cycles of PDT over a 
period of 8 months. The patient reported no adverse 
events during the treatment period, and the average pain 
score during illumination was 4/10.
 The 6 patients with partial response were all treated 
with MAL-PDT: 3 females and 3 males with an age of 
17–62 years. The duration of NL was 1–3 years in 4 pa-
tients, and 8 and 26 years in 1 patient, respectively. Dia-
betes comorbidity was present in 2 of the 6 patients. Le-
sions were ulcerated in 2 patients and hyperpigmented in 
1. All of them had been treated with topical corticoste-
roids prior to PDT. One patient each had previously re-
ceived intralesional corticosteroids, tacrolimus, PUVA 
and cryotherapy. Five of the 6 patients received 2–6 cycles 
of PDT, while 1 received 14 cycles. The pain score during 
PDT ranged from 4/10 to 10/10. After therapy, 3 patients 
had transient erythema, 1 had a bullous reaction and 1 
pustules. The partial response to PDT was observed after 
a period of 1 month to 1 year after therapy. 
 Discussion 
 NL is a cosmetically disturbing disease which may 
cause pain or itching. Therapeutic efforts to treat NL
have been frustrating in the past. Topical and intrale-
sional corticosteroids seem to be the most promising 
drugs, while other cases may respond to systemic thera-
py  [5, 8] .
 The etiology remains subject to discussion. It has been 
proposed that diabetic microangiopathy is the main etio-
logical agent, because similar changes can be seen in dia-
betic retinas and kidneys. Other theories about the devel-
opment of NL suggest deposits of abnormal collagen or of 
immunoglobulins. Furthermore, metabolic changes and 
trauma have been discussed as etiological factors  [3] . 
 This exploratory study focused on a noninvasive ap-
proach for the therapy of NL with the use of a technique 
which offers the possibility of repeated applications. The 
overall response rate was 39% (7/18). Whereas partial 
cure was observed in 6 of 18 patients, dramatic improve-
ment was noted in 1 patient only. 
 The mechanisms responsible for the response to ther-
apy are not yet understood. PDT has been shown to elic-
it immunomodulatory effects that eventually may lead to 
tumor destruction. These effects include the modifica-
tion of cytokine expression, induction of immune-spe-
cific responses, production of interleukin 1  , interleukin 
2, granulocyte colony-stimulating factor and tumor ne-
crosis factor    [10, 11] . Kim et al.  [12] have used PDT to 
successfully cure granuloma annulare, a granulomatous 
disease with certain similarities to NL. Since the actual 
photosensitizer – protoporphyrin IX – has been shown 
to accumulate in lymphatic infiltrates and inhibit T-cell 
proliferation  [13] , it can be hypothesized that this mech-
 Fig. 1. NL on the right lower leg of a female patient (patient 4) be-
fore therapy ( a ) and 7 months after 6 cycles of PDT ( b ). A partial 
response was observed, and the patient was very satisfied with the 
outcome. 
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anism was also effective in NL lesions treated with 
PDT.
 With respect to the characteristics of the responders, 
there seemed to be no association with the duration of the 
disease. The group of responders included patients with 
ulcerations, hyperpigmented lesions, with and without 
diabetes comorbidity and with adverse events like ery-
thema. Regarding comorbidity, clinical appearance and 
adverse events, no association with treatment outcome 
was observed. The only common variable we could iden-
tify was the use of MAL as the sensitizing agent. 
 One limitation of PDT for NL may be the dermal and 
subcutaneous localization of the disease, which is too 
deep to be reached by topical PDT which is most effective 
at a depth of 2–3 mm. Other reasons may be an inade-
quate penetration into altered tissue or the granuloma-
tous character of the disease preventing cellular uptake 
of the photosensitizer.
 Another limiting factor of PDT for NL could be pain. 
Even though it was not observed in a vast number of our 
patients, a few did report very strong discomfort during 
illumination. It has been shown previously that the inten-
sity of pain significantly increased at the second PDT 
treatment  [14] . We also observed an increase in pain with 
the number of PDT sessions. This may be due to an im-
proved penetration of the topical agent because of exco-
riation of the epidermis after the first PDT treatments. 
Alternatively, the nociception in the dermis may have 
changed by the initial PDT itself. This may limit the ac-
ceptance by the patient and therefore the feasible number 
of PDT sessions needed for cure.
 In conclusion, in this multicenter study PDT was 
shown to be effective in the treatment of NL in few cases 
only with a response rate of 39%. We did not find spe-
cific clinical features of NL which would predict a re-
sponse to PDT. A prospective and controlled study should 
now be started on the basis of the presented results to fur-
ther evaluate the efficacy of PDT in NL.
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